Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
Do you rebiopsy grade 1-2 follicular lymphoma if SUV is high by PET?
What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?
Related Questions
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you manage a healthy 31 younger patient with nodular lymphocyte predominant Hodgkin lymphoma with severe hemolytic anemia but no other symptoms that responded to steroids?
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?